Introduction 
Chemotherapy-induced Takotsubo (stress) cardiomyopathy (TC) have been reported for several anticancer agents including antimetabolites, fluoropyrimidines, and molecularly targeted agents(1). Some molecularly targeted agents reportedly cause cardiovascular side effects, including heart failure, arrhythmia (QT prolongation), and myocardial infarction (2). The epidermal growth factor receptor (EGFR) inhibitors except trastuzumab are known to cause less cardiotoxicity than BCR-ABL inhibitors and vascular endothelial growth factor (VEGFR) inhibitors (3). However, osimertinib has been reported more adverse cardiac events than other EGFR inhibitors, including heart failure (4-6). While there exist a few reports of osimertinib-induced heart failure in detail, none have so far reported TC induced by osimertinib. Herein, we report a case of TC caused by osimertinib.